That's News

By Steve Barrett
Friday, November 1, 2019
Specialty: 

Study: Bariatric Surgery Aids Female Sexual Function

A study in Brazil found that women with obesity had greater sexual function after Roux-en-Y gastric bypass.

Sexual dysfunction fell from 62% before the procedure to 19% six months afterward, and mean overall Female Sexual Function Index (FSFI) score rose 19.2%, according to findings published in Sexual Medicine.

Mean BMI dropped from 42 prior to surgery to 30.7 after. All patients had higher FSFI scores six months following surgery, with improvement in areas ranging from desire to arousal to satisfaction, Reuters Health reports.

“The improvement in sexual function is multifactorial,” Cesare Peraglie, MD, a bariatric surgeon at Poinciana Medical Center in Kissimmee, Florida, who was not involved in the study, tells Reuters Health. “Not only are there obvious physical and anatomical reasons, but also mental and psychological reasons (improvement in self-confidence and body image) and medical reasons (resolution of obesity-related illnesses such as diabetes, sleep apnea and dysfunctional hormonal levels).”


Race Linked to Weight Regain After Bariatric Surgery

White patients are less likely to regain weight after Roux-en-Y gastric bypass (RYGB) surgery than are black or Hispanic patients, researchers at Boston University School of Medicine (BUSM) have found.

Their study, which appears in Obesity, notes that RYGB is performed more often in the United States than any type of bariatric surgery except sleeve gastrectomy.

The scientists examined outcomes of RYGB procedures at Boston Medical Center from 2004–2015. Black patients had significantly greater weight regain than white patients, and black and Hispanic patients more often experienced a time of fast weight gain once they achieved their lowest weight following the procedure.

“Racial or ethnic differences in food choices and eating behaviors have long been linked to obesity and cardiovascular disease,” writes corresponding author Nawfal W. Istfan, MD, PhD, Associate Professor of Medicine at BUSM. “However, it is unclear whether there are racial differences in RYGB-mediated changes in appetite hormonal signals, mental health and eating behaviors.”


Endoscopic Devices Expected for Obese Teens

Teens with obesity will soon have the option of endoscopic weight-loss devices, a Mayo Clinic physician predicted at the American Diabetes Association 2019 Scientific Sessions in San Francisco.

Andrew C. Storm, MD, noted in an interview with Medscape Medical News the recent and ongoing FDA approvals of various intragastric balloons for use in adults.

“It is pretty clear that obesity from childhood carries into adulthood,” Dr. Storm said. “Given that these [weight-loss devices] are so safe and have such reasonable impacts in obesity up front, I think the next step will be studying them in young adults.”

Devices approved thus far also have the benefit of being cost-effective, although they must be removed after six months. A gastric balloon that could remain in place for a year is currently being studied, Dr. Storm added.

Phentermine and orlistat are the only FDA-approved drugs for weight loss among obese adolescents, another expert attending the event in San Francisco pointed out. Adults have nine medical therapies available.